FDA Extends Comment Period For Glucose Monitor Guidelines
This article was originally published in The Gray Sheet
Executive Summary
The agency is giving product developers and others an additional month to comment on draft guidelines, issued in January, that distinguish pre-market requirements for glucose meters employed in professional health care settings from those intended for self-monitoring by patients.
You may also be interested in...
FDA Distinguishes Pre-Market Expectations For Professional Vs. Home Glucose Meters
The agency for the first time issued distinct guidance documents for blood glucose meters used in professional settings and those issued over-the-counter for self-monitoring tests by lay-persons. FDA is collecting comments on draft versions of the guidelines.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.